NCT06075758 - A Study of Ribociclib in Combination With Hormonal Therapy in HR+/HER2- Advanced or Metastatic Breast Cancer | Biotech Hunter

Enrollment

550

Participants

Timeline

Start Date

March 7, 2024

Primary Completion Date

June 30, 2025

Study Completion Date

June 30, 2025

Conditions

Breast Cancer

Interventions

OTHER

ribociclib

"There is no treatment allocation for NIS trials, patients on administered ribociclib by prescription will be enrolled.~Treatment plan represents the prescription."

Trial Locations (4)

1331

RECRUITING

Novartis Investigative Site, Muscat

11211

RECRUITING

Novartis Investigative Site, Riyadh

11941

RECRUITING

Novartis Investigative Site, Amman

Unknown

RECRUITING

Novartis Investigative Site, Al Ain Abu Dhabi